OncoMatch

OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/EGFR

Lung Cancer — Non-Small Cell (NSCLC)EGFR Clinical Trials

178 recruiting trials·Updated daily from ClinicalTrials.gov

EGFR mutations — primarily exon 19 deletions and exon 21 L858R substitutions — drive tumor growth in about 15% of non-squamous NSCLC in Western populations and up to 50% in East Asian populations. Osimertinib, a third-generation EGFR inhibitor, is the current first-line standard for advanced disease and the approved adjuvant standard after resection (ADAURA). Trials investigate novel EGFR inhibitors, antibody-drug conjugates, and strategies to overcome on-target resistance mutations such as C797S.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting EGFR Lung Cancer — Non-Small Cell (NSCLC) trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 3603 US sites

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

National Cancer Institute (NCI)

Phase 337 US sites

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

AstraZeneca

Phase 3

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Taiho Oncology, Inc.

Phase 3

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 2/Phase 3

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Hansoh BioMedical R&D Company

Phase 3

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Region Skane

Additional trials

More EGFR Lung Cancer — Non-Small Cell (NSCLC) trials

See all in search →
Phase 2
22 international trials (no US sites)
NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerPhase 2/Phase 3NCT06829459A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsPhase 3NCT06927986Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）Phase 3NCT06674343Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical MutationsPhase 3NCT06956001Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationPhase 3NCT07016126D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLCPhase 3NCT07182682A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryPhase 3NCT06745908Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InPhase 3NCT07738172Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerPhase 3NCT06041776Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsPhase 3NCT04853342To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyPhase 3NCT06838273A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 3NCT04951635A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerPhase 3NCT07185997Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsPhase 3NCT06598527Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective StudyPhase 3NCT07050043Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCPhase 3NCT05852990Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLCPhase 3NCT05768490Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain MetastasesPhase 3NCT06908993Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedPhase 3NCT07362459A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.Phase 3NCT07100080Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)Phase 2/Phase 3NCT07155187A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerPhase 2/Phase 3
Related therapies

FDA-approved therapies for EGFR Lung Cancer — Non-Small Cell (NSCLC)

Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.

OsimertinibThird-generation EGFR inhibitorEGFR-mutant (ex19del or L858R) NSCLC, first-line and adjuvantAmivantamabEGFR/MET bispecific antibodyEGFR exon 20 insertion NSCLC, after platinum-based chemotherapy (monotherapy, FDA 2021)EGFR del19/L858R or exon 20 insertion NSCLC, first-line, in combination with lazertinib or carboplatin-pemetrexed (FDA 2024)
Other Lung Cancer — Non-Small Cell (NSCLC) biomarkers

Browse other molecular targets with active Lung Cancer — Non-Small Cell (NSCLC) trials.

ALKROS1PD-L1 (CD274)KRASMETHER2 (ERBB2)BRAFRETNTRK1NTRK2NTRK3
← All Lung Cancer — Non-Small Cell (NSCLC) clinical trials